{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:12Z","timestamp":1707523932396},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,9]]},"DOI":"10.7759\/cureus.46718","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:23:49Z","timestamp":1696847029000},"source":"Crossref","is-referenced-by-count":0,"title":["The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Atique","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqtadar","family":"Seerat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Atique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayyaba","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14670\/HH-29.177","article-title":"CD138 (syndecan-1) expression in health and disease","volume":"29","author":"Palaiologou M","year":"2014","unstructured":"Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. Histol Histopathol. 2014, 29:177-89. 10.14670\/HH-29.177","journal-title":"Histol Histopathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4928315","article-title":"Prevalence of syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues","volume":"2019","author":"Kind S","year":"2019","unstructured":"Kind S, Merenkow C, B\u00fcscheck F, et al.. Prevalence of syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues. Dis Markers. 2019, 2019:4928315. 10.1155\/2019\/4928315","journal-title":"Dis Markers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90112-4","article-title":"Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?","volume":"83","author":"Schlessinger J","year":"1995","unstructured":"Schlessinger J, Lax I, Lemmon M,. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. Cell. 1995, 83:357-60. 10.1016\/0092-8674(95)90112-4","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2018.02.008","article-title":"Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGF\u03b21 action and upregulating MMP14","volume":"68-69","author":"Reg\u0151s E","year":"2018","unstructured":"Reg\u0151s E, Abdelfattah HH, Reszegi A, et al.. Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGF\u03b21 action and upregulating MMP14. Matrix Biol. 2018, 68-69:474-89. 10.1016\/j.matbio.2018.02.008","journal-title":"Matrix Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1110-07","article-title":"Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma","volume":"80","author":"Metwaly HA","year":"2012","unstructured":"Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM. Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm. 2012, 80:179-88. 10.3797\/scipharm.1110-07","journal-title":"Sci Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i1.379","article-title":"Proteoglycans in liver cancer","volume":"22","author":"Baghy K","year":"2016","unstructured":"Baghy K, T\u00e1trai P, Reg\u0151s E, Kovalszky I. Proteoglycans in liver cancer. World J Gastroenterol. 2016, 22:379-93. 10.3748\/wjg.v22.i1.379","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00617-0","article-title":"Syndecan-1 in liver diseases","volume":"26","author":"Reg\u0151s E","year":"2020","unstructured":"Reg\u0151s E, Kar\u00e1szi K, Reszegi A, Kiss A, Schaff Z, Baghy K, Kovalszky I. Syndecan-1 in liver diseases. Pathol Oncol Res. 2020, 26:813-9. 10.1007\/s12253-019-00617-0","journal-title":"Pathol Oncol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12711","article-title":"Hepatitis C virus infection propagates through interactions between syndecan-1 and CD81 and impacts the hepatocyte glycocalyx","volume":"19","author":"Grigorov B","year":"2017","unstructured":"Grigorov B, Reungoat E, Gentil Dit Maurin A, et al.. Hepatitis C virus infection propagates through interactions between syndecan-1 and CD81 and impacts the hepatocyte glycocalyx. Cell Microbiol. 2017, 19:10.1111\/cmi.12711","journal-title":"Cell Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/07853899608999076","article-title":"The role of syndecan-1 in malignancies","volume":"28","author":"Inki P","year":"1996","unstructured":"Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med. 1996, 28:63-7. 10.3109\/07853899608999076","journal-title":"Ann Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19971021)74:5<482::aid-ijc2>3.0.co;2-#","article-title":"Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential","volume":"74","author":"Matsumoto A","year":"1997","unstructured":"Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer. 1997, 74:482-91. 10.1002\/(sici)1097-0215(19971021)74:5&lt;482::aid-ijc2&gt;3.0.co;2-#","journal-title":"Int J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(03)00336-8","article-title":"Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma","volume":"34","author":"Harada K","year":"2003","unstructured":"Harada K, Masuda S, Hirano M, Nakanuma Y. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 2003, 34:857-63. 10.1016\/s0046-8177(03)00336-8","journal-title":"Hum Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.10.036","article-title":"Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer","volume":"45","author":"Szarvas T","year":"2014","unstructured":"Szarvas T, Reis H, Kramer G, et al.. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol. 2014, 45:674-82. 10.1016\/j.humpath.2013.10.036","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12264","article-title":"Expression of syndecan-1 in chronic liver diseases: correlation with hepatic fibrosis","volume":"35","author":"Charchanti A","year":"2021","unstructured":"Charchanti A, Kanavaros P, Koniaris E, Kataki A, Glantzounis G, Agnantis NJ, Goussia AC. Expression of syndecan-1 in chronic liver diseases: correlation with hepatic fibrosis. In Vivo. 2021, 35:333-9. 10.21873\/invivo.12264","journal-title":"In Vivo"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho WJ","year":"2021","unstructured":"Ho WJ, Zhu Q, Durham J, et al.. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021, 2:891-903. 10.1038\/s43018-021-00234-4","journal-title":"Nat Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/174193-the-intensity-and-pattern-of-syndecan-1-cd138-expression-in-normal-and-diseased-livers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:57Z","timestamp":1707508497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/174193-the-intensity-and-pattern-of-syndecan-1-cd138-expression-in-normal-and-diseased-livers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.46718","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}